COMMUNIQUÉS West-GlobeNewswire

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
30/06/2026
Vafseo ® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent [...]
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
30/06/2026
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated modulation of [...]
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
30/06/2026
Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026 JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a [...]
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
30/06/2026
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide ® commercial progress HOUSTON, June 30, 2026 (GLOBE NEWSWIRE [...]
Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer
30/06/2026
- Proceeds will fund advancement of AR ON degrader, FX-111, to proof of concept and preclinical development of AR ON RIPTAC program - Veteran biotech executive, Anna Protopapas, appointed as CEO to guide company through [...]
Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants
30/06/2026
LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a leading medical device and healthcare services company focused on the treatment of breathing‑ [...]
Weight Watchers Med+ Establishes Access to GLP-1s Through Medicare GLP-1 Bridge Program
30/06/2026
Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program. NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight [...]
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
30/06/2026
Expanding manufacturing capabilities is part of the Company’s cost reduction strategy and supports global expansion HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and [...]
Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial
30/06/2026
Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies for trial enrollment and precisely evaluate treatment response BOSTON, June 30, 2026 (GLOBE NEWSWIRE [...]
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
30/06/2026
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for [...]
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
30/06/2026
Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12 SOLANA BEACH, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage [...]
New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
30/06/2026
Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers Across both studies, mogamulizumab was associated with improved survival [...]
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
30/06/2026
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 ALPHARETTA, Ga., June 30, 2026 (GLOBE NEWSWIRE) -- [...]
TerrAscend Signs Agreement to Acquire Fifth Dispensary in New Jersey
30/06/2026
Aunt Mary’s, a high-performing dispensary in Hunterdon County, generates over $10 million in annualized revenue Transaction expected to be immediately accretive on an EBITDA and free cash flow basis, further extending [...]
Jushi Celebrates Enactment of Virginia Adult-Use Cannabis Legislation
30/06/2026
BOCA RATON, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (CSE: JUSH ) (OTCQX: JUSHF ) ("Jushi" or the "Company"), a vertically integrated, multi-state cannabis operator, celebrates the enactment of [...]
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
30/06/2026
InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient development plan to [...]
NurExone Announces Closing of Non-Brokered Private Placement
30/06/2026
TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exosome-based [...]
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
30/06/2026
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for [...]
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
30/06/2026
Allowed Claims Cover a Method of Treating Netherton Syndrome with a Topical Serine Protease Inhibitor and an Anti-Inflammatory Agent, Including in Patients with SPINK5 Mutations ASHBURN, Va., June 30, 2026 (GLOBE [...]

Pages